---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027724"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T15:33:39.301897+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q2 revenue up 31% to $5.8M, net loss widens to $9.8M; cash $4.5M

## Summary
- Revenue $5.8M (+31% YoY); net loss $9.8M ($7.23/share) vs $0.9M loss in Q2 2022.
- Cash $4.5M, down from $17.2M at Dec 31, 2022; equity investment in Biofrontera AG $5.9M.
- Founder Hermann Luebbert named CEO, continues as Executive Chairman.
- Affirms FY 2023 revenue growth at least 25%; expects cash flow positive within ~1.5 years.

## SEC filing metadata
- accession: 0001493152-23-027724
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/0001493152-23-027724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027724
- JSON: https://secwatch.observer/filing/0001493152-23-027724.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027724.txt

## Key facts
- Earnings Releases
  Biofrontera Inc. reported the six months ended June 30, 2023 results: revenue $14.6 million, net income $17.3 million, EPS $(12.73) per share. Guidance reaffirmed.
  - Period: the six months ended June 30, 2023
  - Revenue: $14.6 million
  - Net income: $17.3 million
  - EPS: $(12.73) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items. Six Month Financial Results Total revenues were $14.6 million for the first half of 2023 compared with $14.2 million for the first half of 2022. The increase was primarily driven by a higher volume of Ameluz sales due to the sales team
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/0001493152-23-027724-index.htm
- Earnings Releases
  Biofrontera Inc. reported the three months ended June 30, 2023 results: revenue $5.8 million, net income $9.8 million, EPS $(7.23) per share. Guidance reaffirmed.
  - Period: the three months ended June 30, 2023
  - Revenue: $5.8 million
  - Net income: $9.8 million
  - EPS: $(7.23) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: and six months ended June 30, 2023 and provided a business update. Highlights from the second quarter of 2023 and subsequent weeks included the following: ● Total revenues were $5.8 million, an increase of 31% from the comparable prior-year period ● Cash and cash equivalents were $4.5 million as of June 30, 2023, compared with $17.2 million as of December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/0001493152-23-027724-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.